White label ELPA - ClinicalTrials.eu

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

Not recruiting

2 1 1
Investigated Diseases:
- Breast cancer metastatic
- HER2 positive breast cancer
Investigated Drugs:
- Trastuzumab Deruxtecan
Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Not recruiting

2 1
Investigated Drugs:
- Dc-806
Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Not recruiting

1 1 1 1
Investigated Diseases:
- Hodgkin’s disease
Investigated Drugs:
- Nivolumab
- Relatlimab
Study Comparing OXU-001 and Intravitreal Dexamethasone for Patients with Diabetic Macular Edema

Not recruiting

2 1 1 1
Investigated Diseases:
- Diabetic retinal oedema
Investigated Drugs:
- Dexamethasone Acetate Ph. Eur.
- Dexamethasone
Study of Atezolizumab and RP1 for Patients with Early-Stage Triple-Negative Breast Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
- Rp1
- Atezolizumab
Study on Danicamtiv for Patients with Primary Dilated Cardiomyopathy Due to MYH7 or TTN Gene Variants

Not recruiting

2 1 1
Investigated Diseases:
- Dilated cardiomyopathy
Investigated Drugs:
- Danicamtiv
Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Not recruiting

3 1
Investigated Drugs:
- Ruxolitinib
+1
Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy

Not recruiting

3 1 1
Investigated Drugs:
- Secukinumab
Study on the Long-Term Safety and Effectiveness of Amlitelimab for Adults with Moderate to Severe Atopic Dermatitis

Not recruiting

2 1 1 1
Investigated Drugs:
- Amlitelimab
+2
Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Triple negative breast cancer
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies